Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHR-1316 + SHR-2002 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHR-1316 | SHR 1316|SHR1316|Adebrelimab|HTI 1088|HTI-1088|HTI1088 | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 | SHR-1316 is a monoclonal antibody that targets PD-L1 (CD274), potentially resulting in antitumor activity (PMID: 33760397). | |
| SHR-2002 | SHR2002|SHR 2002 | PVRIG Antibody 5 TIGIT Antibody 20 | SHR-2002 is a bispecific antibody that targets PVRIG (CD112R) and TIGIT, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 39851063). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05082545 | Phase I | SHR-1316 + SHR-2002 | Phase I Study of SHR-2002 + SHR-1316 in Patients With Advanced Malignant Tumors | Completed | AUS | 0 |